Open AccessCOVID-19 Vaccines and Vaccination Report: The Nigeria Perspective
Author(s) -
Moore Ikechi Mike-Ogburia,
Jonathan Nyebuchi,
Felix Eedee Konne,
Robin Jacob
Publication year - 2021
Publication title -
journal of advances in microbiology
Language(s) - English
Resource type - Journals
ISSN - 2456-7116
DOI - 10.9734/jamb/2021/v21i1230413
Subject(s) - vaccination , medicine , coronavirus , adverse effect , virology , covid-19 , immunity , immunology , disease , infectious disease (medical specialty) , immune system
COVID-19 vaccine like other vaccines is developed to produce acquired immunity against the virus which causes coronavirus disease. The spread of the virus led to quick study by various science laboratories all over the world on the preventive role and the mortality rate reduction potential of covid vaccines. Celebration has been witnessed in different part of the world for the role the vaccines played against various cases arising from coronavirus infection. This review focused on the adverse event of coronavirus vaccines with perspective to the Nigerian populace. The type of vaccines approved for use by the WHO include; viral vector vaccines which has the Oxford-Astrazenca in its class, RNA vaccines, whole virus vaccines (having the Sinopharm, and Sinovac in it class), and protein subunit vaccines (with Novavax COVID-19 vaccines and (ESI, 2021), EpiVacCorona in it class). In Nigeria, about 8,439 mild adverse reactions have been reported by the National Health Care Development Agency (NPHCDA), following the administration of the first doses of the Oxford-AstraZeneca COVID-19 vaccine. The report showed that out of over a million persons who received the vaccine, 8,439 persons showed mild adverse effects, while 52 persons suffered moderate to severe adverse events on receiving the jab. Generally, the vaccine has proven to be effective in combating and limiting infection and spread of covid-19 among the citizenry.